FOGHORN THERAPEUTICS INC (FHTX)
Health Care · Precision oncology biotechnology · NASDAQ
Precision biotechnology company developing chromatin-targeting small molecule therapeutics to treat cancer and other serious diseases by correcting abnormal gene expression.
What FOGHORN THERAPEUTICS INC does
Foghorn Therapeutics is a clinical-stage precision therapeutics biotechnology company developing small molecule drugs targeting the chromatin regulatory system, which controls gene expression in cells. The company's proprietary Gene Traffic Control® platform enables discovery and validation of novel targets within chromatin remodeling complexes, transcription factors, and related factors that are dysregulated in cancer and other diseases. Foghorn currently has more than seven programs in development, with FHD-909 (a selective SMARCA2/BRM inhibitor) in Phase 1 clinical trials through a collaboration with Eli Lilly. The company is biology-first in its approach, using protein degraders, allosteric enzymatic inhibitors, and transcription factor disruptors as appropriate for each target.
Themes: precision medicine, chromatin regulation, oncology, epigenetics, gene expression modulation, synthetic lethality
Fundamentals
- Price$7.07 as of 2026-08-21 close
- Market cap$420M as of 2026-08-21
- 1-year return+40.3% 2025-08-21 close $5.04 → 2026-08-21 close $7.07
- P/En/a negative earnings
- Net margin-175.8% as of 2026-08-24
- ROE-301.6% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+52.0% as of 2026-08-24
- Revenue CAGR (3y)+17.1% SEC XBRL
- Beta2.97 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How FHTX compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How FOGHORN THERAPEUTICS INC looks technically
FOGHORN THERAPEUTICS INC (FHTX) is trading 40.4% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 5 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 34, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 72, in overbought territory (above 70). It just made a new 20-day high, pushing above its recent trading range.
Trend
9
| Distance from the 200-day | it is trading 40.4% above its 200-day average, the long-term trend line — a longer-term uptrend | +40.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $5.27 | $5.27 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $5.04 | $5.04 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 21 calendar days ago — the swings before that are what the structure reading is measured on | 21 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 4.405. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 5 trading days ago — a "golden cross", a bullish long-term signal | 5 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 40.4% above | +40.4% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 34, with buyers in control | 34.1 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 72, in overbought territory (above 70) | 71.8 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($4.63 to $7.61) — its "stochastic" reading is 82 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 81.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $7.61 | $7.61 |
|---|---|---|
| From the 52-week high | it is 7.1% below its 52-week high (its highest price of the past year) | -7.1% |
| Above the 52-week low | it is 116.2% above its 52-week low (its lowest price of the past year) | +116.2% |
| Below the 52-week high | it is 7.1% below its highest point of the past year | 7.1% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $24.16 (set on 2022-01-03) | $24.16 |
| Given back of the 52-week move | over the past year its closes ranged ($3.53 to $7.07), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.77 to $4.88. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 70.7% below its all-time high | -70.7% |
| Nearest price level | it is trading 1.8% above a support level at $6.95 — a price it turned at twice since 2024-10-10, most recently on 2026-01-13. Since 2024-08-21 it has 14 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.8% |
| All-time low | its lowest closing price on record is $2.70 (set on 2024-02-05) | $2.70 |
| Above the all-time low | it is 161.9% above its all-time low | +161.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 96% of the past ~6 months) | 96th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4532 between its high and its low — about 6.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4532 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $4.04 and $7.68 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $4.04 – $5.86 – $7.68 |
| Typical daily range (% of price) | its price moves about 6.4% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.4% |
| Stretch from the 200-day average | it is trading 4.5 daily ranges above its 200-day average price (40.4% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.97× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.3% |
|---|---|---|
| Open gap | it gapped 2.8% above the previous close 2 sessions ago and has not traded back through the level it left behind at 6.75 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.8% |
| Gap filled | a 2.9% gap up opened on 2026-07-27 has been "filled" 17 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 17 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 34.7 percentage points (the stock gained 37.0% while the market gained 2.3%) | +34.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 66.9 percentage points (the stock gained 70.0% while the market gained 3.1%) | +66.9% |
| vs market, 6 months | over the past 6 months this stock beat the market by 12.3 percentage points (the stock gained 23.4% while the market gained 11.1%) | +12.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 19.8 percentage points (the stock gained 40.3% while the market gained 20.5%) | +19.8% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 31% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 5.1% of the share price. | +30.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 33% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $5.33 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +32.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $6.66 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +6.1% |
Price levels it has turned at before
FHTX last closed at $7.07 on 2026-08-21. Since 2024-08-21 it has turned at 14 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $6.95 | Support | 1.8% below the last close | turned there twice · 2024-10-10 to 2026-01-13 |
| $6.62 | Support | 6.4% below the last close | turned there twice · 2025-02-18 to 2026-07-08 |
| $5.97 | Support | 15.6% below the last close | turned there three times · 2025-12-22 to 2026-02-25 |
| $8.40 | Resistance | 18.8% above the last close | turned there twice · 2024-10-16 to 2024-12-02 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $4.41.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $7.43 and $9.31 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $4.41.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Broke out to a new 20-day high · in a strong, established uptrend (ADX) | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.10 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$11.44 range $9.00 – $14.00; median $12.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for FHTX
- Consensus EPS estimate-$0.24 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical trial risk: FHD-909 is only in Phase 1; no guarantee of efficacy or regulatory approval; development timelines and costs for oncology programs are substantial.","Dependency on Eli Lilly collaboration: Material portion of strategy relies on Lilly partnership for SMARCA2 and undisclosed target programs; changes to the collaboration could impact pipeline progress.","Supply chain and geopolitical exposure: Reliance on CDMOs and CROs in China and other foreign countries creates vulnerability to regulatory changes (e.g., China's Anti-Foreign Sanctions Law), trade restrictions, and geopolitical instability."]
What changed in the latest 10-Q
AI-assisted comparison of FHTX's 10-Q filed 2026-05-07 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to Form 10-K for fiscal year ended December 31, 2025 (newer filing, filed 2026-05-07)
- Description of January 9, 2026 securities purchase agreements with life sciences investors (newer filing, filed 2026-05-07)
- Details on 2,030,314 shares of Common Stock issuance (newer filing, filed 2026-05-07)
- Details on 5,421,250 Pre-Funded Warrants issuance (newer filing, filed 2026-05-07)
- Details on 7,451,564 Series Warrants issuance with two series specified (newer filing, filed 2026-05-07)
- Specification of Series 1 Warrants: 3,725,782 shares at $13.42 exercise price expiring June 30, 2027 (newer filing, filed 2026-05-07)
- Specification of Series 2 Warrants: 3,725,782 shares at $20.13 exercise price expiring December 31, 2030 (newer filing, filed 2026-05-07)
- January 2026 Offering closed on January 13, 2026 with gross proceeds of approximately $50.0 million (newer filing, filed 2026-05-07)
- Offering costs of approximately $0.3 million treated as reduction to equity (newer filing, filed 2026-05-07)
- Statement that no underwriter or placement agent participated in January 2026 offering (newer filing, filed 2026-05-07)
- Removed:
- Reference to Form 10-K for fiscal year ended December 31, 2024 (older filing, filed 2025-11-05)
- Description of May 2024 underwriting agreement with Jefferies LLC, TD Securities (USA) LLC and Evercore Group LLC (older filing, filed 2025-11-05)
- Details on May 2024 offering of 12,743,039 shares at $5.51 per share (older filing, filed 2025-11-05)
- Details on May 2024 pre-funded warrants to purchase 7,220,794 shares at $5.5099 per warrant (older filing, filed 2025-11-05)
- Statement that May 2024 offering closed on May 22, 2024 with net proceeds of $102.8 million (older filing, filed 2025-11-05)
- Specific financial results: nine months ended September 30, 2025 net loss of $52.6 million (older filing, filed 2025-11-05)
- Specific financial results: year ended December 31, 2024 net loss of $86.6 million (older filing, filed 2025-11-05)
- Specific financial results: accumulated deficit of $610.8 million as of September 30, 2025 (older filing, filed 2025-11-05)
- Reworded:
- Lilly Collaboration Agreement description changed from 'U.S. 50/50 U.S. co-development and co-commercialization agreement' to more detailed language specifying 'joint programs' with U.S. profit and expense share, worldwide research and development expense share, and ex-U.S. royalties (newer filing, filed 2026-05-07)
- Lilly collaboration programs description changed from 'three discovery programs from Foghorn's proprietary Gene Traffic Control platform' to 'three discovery programs that will leverage Foghorn's proprietary Gene Traffic Control platform which are subject to customary royalties and milestones and are not subject to co-development, co-commercialization rights' (newer filing, filed 2026-05-07)
- FHD-909 Phase 1 timing description changed from 'dosed its first patient' to 'the first patient was dosed' (newer filing, filed 2026-05-07)
- FHD-909 description reordered: moved 'a selective allosteric ATPase inhibitor of SMARCA2' description to follow 'FHD-909' instead of appearing after 'developed in collaboration with Lilly' (newer filing, filed 2026-05-07)
- Reference to financial statements changed from 'condensed consolidated statements' to 'consolidated statements' in Lilly cost-share sentence (newer filing, filed 2026-05-07)
- Description of Lilly stock purchase agreement updated to specify 'par value $0.0001 per share' for Common Stock (newer filing, filed 2026-05-07)
- Notes:
- Both texts appear truncated at the end and do not contain complete MD&A sections; comparison limited to available text
- The newer filing contains an apparent incomplete sentence at the very end ('We have incurred significant operatin') suggesting document truncation
- The older filing also contains truncated text at the end ('expand the capabilities of our pl') suggesting document truncation
- Some financial results and operational information present in older filing are not included in the newer filing excerpt, but this may be due to truncation rather than actual removal
Risk Factors
- Added:
- Added reference to 'China's Anti-Foreign Sanctions Law and its implementing regulations' in forward-looking statements (2026-05-07 filing)
- Added 'ongoing and potential geopolitical instability and armed conflicts' as separate bullet point in forward-looking statements (2026-05-07 filing)
- Removed:
- Removed 'statutory and regulatory developments' language was replaced with narrower focus on China specifically (2026-05-07 filing)
- Removed 'tariff uncertainty' from economic conditions list (2026-05-07 filing)
- Removed 'stock market volatility' reference from general economic conditions (2026-05-07 filing)
- Removed 'the impact of inflation, interest rates, and stock market volatility on our operation and our ability to raise additional capital' bullet point (2026-05-07 filing)
- Removed 'the expected trends in our expenses and capital requirements as they relate to our ongoing activities' bullet point (2026-05-07 filing)
- Removed specific geopolitical references to 'effects of a prolonged U.S. government shutdown and armed conflicts in Ukraine, Gaza, and the Red Sea' (2026-05-07 filing)
- Removed reference to 'FHD-909, our future products' in IP protection language; now reads 'current and future product candidates' (2026-05-07 filing)
- Reworded:
- Changed 'regulatory developments in the United States and foreign countries' to 'statutory and regulatory developments in the United States and foreign countries, especially in China' (2026-05-07 filing)
- Changed 'general financial and economic conditions' to 'general economic conditions' (2026-05-07 filing)
- Changed reference from Form 10-K 'for the fiscal year ended December 31, 2024' to 'for the fiscal year ended December 31, 2025' (2026-05-07 filing)
- Changed 'geopolitical events and uncertainty' to 'ongoing and potential geopolitical instability and armed conflicts' (2026-05-07 filing)
- Notes:
- Financial statements compare different periods (Q1 2026 vs Q3 2025 and full nine months 2025) so changes in financial metrics reflect different reporting periods, not filing changes
- Text provided appears truncated at end of newer filing; full Risk Factors section content not provided for comparison
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for FHTX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding FHTX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 9,698,289
- Reported value $46,357,821
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
FHTX had 1,603,855 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
FHTX had 2.70% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.65 days to cover at the same settlement.
- Reported short interest (shares) 1,603,855
- Short interest (% of shares outstanding) 2.70%
- Prior settlement (shares) 1,535,862
- Reported change 4.43%
- Days to cover (reported) 7.65
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Constellation Pharmaceuticals (acquired by MorphoSys)
- Epizyme (acquired by Ipsen)
- Astex Pharmaceuticals (Otsuka)
- H3 Biomedicine (Eisai)
- Karyopharm Therapeutics (KPTI)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare FHTX vs…
FOGHORN THERAPEUTICS INC is found in…
Frequently asked questions
What does FOGHORN THERAPEUTICS INC (FHTX) do?
Foghorn Therapeutics is a clinical-stage precision therapeutics biotechnology company developing small molecule drugs targeting the chromatin regulatory system, which controls gene expression in cells. The company's proprietary Gene Traffic Control® platform enables discovery and validation of novel targets within chromatin remodeling complexes, transcription factors, and related factors that are dysregulated in cancer and other diseases.
What sector is FOGHORN THERAPEUTICS INC (FHTX) in?
FOGHORN THERAPEUTICS INC (FHTX) is classified in the Health Care sector. Its industry is Precision oncology biotechnology. It trades on NASDAQ.
Who are FOGHORN THERAPEUTICS INC's (FHTX) competitors?
Notable peers of FOGHORN THERAPEUTICS INC (FHTX) include Constellation Pharmaceuticals (acquired by MorphoSys), Epizyme (acquired by Ipsen), Astex Pharmaceuticals (Otsuka), H3 Biomedicine (Eisai) and Karyopharm Therapeutics. This peer set is informational only — not financial advice.
Is FOGHORN THERAPEUTICS INC (FHTX) overbought or oversold right now?
FOGHORN THERAPEUTICS INC (FHTX) is currently in overbought territory (its 14-day RSI is 72, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on FHTX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.